Johnson previously led Exactech as CEO, managing a global workforce of 900 employees across 13 countries. During his tenure, he transformed the company's Extremities Business Unit, growing the Equinoxe shoulder platform into a dominant international franchise. His background also includes serving as a board director for JointMedica Ltd, where he guided the commercialization of an FDA-designated breakthrough hip resurfacing technology.
Atreon CEO Ronald Bracken cited Johnson’s dual proficiency in operational strategy and regulatory navigation as critical assets for the company’s next phase of growth. Johnson holds a degree in Business Economics from Brown University and began his career in investment banking at firms including Morgan Keegan and Raymond James Capital. He now shifts his focus to Atreon’s synthetic matrices, which are designed to improve tissue remodeling and provide a consistent alternative to traditional, tissue-derived orthopedic products.

Comments (0)
No comments yet. Be the first!